Gait instability in valproate-treated patients: Call to measure ammonia levels
- 23 April 2017
- journal article
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 136 (5) , 401-406
Abstract
Hyperammonemia induced by valproate (VPA) treatment may lead to several neurological and systemic symptoms as well as to seizure exacerbation. Gait instability and recurrent falls are rarely mentioned as symptoms, especially not as predominant ones. We report five adult patients with frontal lobe epilepsy (FLE) who were treated with VPA and in whom a primary adverse effect was unstable gait and falls. There were four males and one female patients with FLE, 25-42-year-old, three following epilepsy surgery. All of them were treated with antiepileptic drug polytherapy. Gait instability with falls was one of the principal sequelae of the treatment. Patients also exhibited mild encephalopathy (all patients) and flapping tremor (three patients) that developed following the addition of VPA (three patients) and with chronic VPA treatment (two patients). VPA levels were within the reference range. Serum ammonia levels were significantly elevated (291-407 μmole/L, normal 20-85) with normal or slightly elevated liver enzymes. VPA dose reduction or discontinuation led to the return of ammonia levels to normal and resolution of the clinical symptoms, including seizures, which disappeared in two patients and either decreased in frequency or became shorter in duration in the other three. Gait instability due to hyperammonemia and VPA treatment is probably under-recognized in many patients. It can develop when the VPA levels are within the reference range and with normal or slightly elevated liver enzymes.Keywords
This publication has 19 references indexed in Scilit:
- Valproate-Associated Parkinsonism: A Critical Review of the LiteratureCNS Drugs, 2016
- Risk Factors of Hyperammonemia in Patients With Epilepsy Under Valproic Acid TherapyMedicine, 2014
- Adverse drug reactions induced by valproic acidClinical Biochemistry, 2013
- Unilateral basal-ganglia involvement likely due to valproate-induced hyperammonemic encephalopathyNeurological Sciences, 2011
- Reversible dementia and gait disturbance after prolonged use of valproic acidSeizure: European Journal of Epilepsy, 2011
- Valproate monotherapy induced-delirium due to hyperammonemia: A report of three adult cases with different types of presentationIndian Journal of Psychiatry, 2008
- Valproate-associated Hyperammonemic EncephalopathyThe Journal of the American Board of Family Medicine, 2007
- Different clinical manifestations of hyperammonemic encephalopathyEpilepsy & Behavior, 2007
- Hippocampal Involvement in Valproate-Induced Acute Hyperammonemic EncephalopathyArchives of Neurology, 2006
- Pharmacological and Therapeutic Properties of ValproateCNS Drugs, 2002